Charles Schwab Investment Management Inc Xilio Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 11,925 shares of XLO stock, worth $11,328. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,925
Previous 11,925
-0.0%
Holding current value
$11,328
Previous $6,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding XLO
# of Institutions
32Shares Held
10MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA2.81MShares$2.67 Million0.46% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.37 Million19.12% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD1.44MShares$1.37 Million0.04% of portfolio
-
Atlas Venture Life Science Advisors, LLC993KShares$943,2660.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA903KShares$857,4040.0% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $26.1M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...